| Company Name: |
Shanghai Synchem Pharma Co., ltd
|
| Tel: |
21-619849051-1 18521059765 |
| Email: |
synchempharma@aliyun.com |
| Products Intro: |
Product Name:N-[(1R)-5-(1,1-Dimethylethyl)-2,3-dihydro-1H-inden-1-yl]-N'-1H-indazol-4-ylurea CAS:808756-71-0 Purity:95%+
|
N-[(1R)-5-(1,1-Dimethylethyl)-2,3-dihydro-1H-inden-1-yl]-N'-1H-indazol-4-ylurea manufacturers
- ABT 102
-
- $117.00
-
2026-04-20
- CAS:808756-71-0
- Purity: 99.53%
- Supply Ability: 10g
|
| | N-[(1R)-5-(1,1-Dimethylethyl)-2,3-dihydro-1H-inden-1-yl]-N'-1H-indazol-4-ylurea Basic information |
| Product Name: | N-[(1R)-5-(1,1-Dimethylethyl)-2,3-dihydro-1H-inden-1-yl]-N'-1H-indazol-4-ylurea | | Synonyms: | N-[(1R)-5-(1,1-Dimethylethyl)-2,3-dihydro-1H-inden-1-yl]-N'-1H-indazol-4-ylurea;ABT-102;1-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-3-(1H-indazol-4-yl)urea;N-(5-tert-Butylindan-1-yl)-N'-(1H-indazol-4-yl)urea;ABT-102
(ABT102);CHEMBL398338;Urea, N-[(1R)-5-(1,1-dimethylethyl)-2,3-dihydro-1H-inden-1-yl]-N'-1H-indazol-4-yl-;ABT 102, 10 mM in DMSO | | CAS: | 808756-71-0 | | MF: | C21H24N4O | | MW: | 348.44146 | | EINECS: | | | Product Categories: | | | Mol File: | 808756-71-0.mol | ![N-[(1R)-5-(1,1-Dimethylethyl)-2,3-dihydro-1H-inden-1-yl]-N'-1H-indazol-4-ylurea Structure](CAS2/GIF/808756-71-0.gif) |
| | N-[(1R)-5-(1,1-Dimethylethyl)-2,3-dihydro-1H-inden-1-yl]-N'-1H-indazol-4-ylurea Chemical Properties |
| Boiling point | 529.5±42.0 °C(Predicted) | | density | 1.24 | | pka | 13.04±0.20(Predicted) |
| | N-[(1R)-5-(1,1-Dimethylethyl)-2,3-dihydro-1H-inden-1-yl]-N'-1H-indazol-4-ylurea Usage And Synthesis |
| Uses | ABT-102 is a potent and highly selective Vanilloid Receptor (TRPV1) receptor antagonist. ABT-102 potently and reversibly increases heat pain thresholds and reduced painfulness of suprathreshold oral/cutaneous heat. ABT-102 reduces nociceptive responses of animals in models of inflammatory, bone cancer, postoperative, and osteoarthritic pain[1][2]. | | IC 50 | TRPV1 | | References | [1] Lukin K, et al. Development of a Large Scale Asymmetric Synthesis of Vanilloid Receptor (TRPV1) Antagonist ABT-102. Organic Process Research & Development, 2007, 11(3):578-584. [2] Rowbotham MC, et al. Oral and cutaneous thermosensory profile of selective TRPV1 inhibition by ABT-102 in a randomized healthy volunteer trial. Pain. 2011 May;152(5):1192-1200. DOI:10.1016/j.pain.2011.01.051 |
| | N-[(1R)-5-(1,1-Dimethylethyl)-2,3-dihydro-1H-inden-1-yl]-N'-1H-indazol-4-ylurea Preparation Products And Raw materials |
|